Analysis for CME

📈 Growth & Financial Trajectory

Over eight quarters CME's revenue progressed from about $1.5325B (2024 Q2) to about $1.7062B (2026 Q2), an ~11% rise. Net income to the parent grew from about $872.1M (start shown with data) to $1.0418B, signaling a constructive profitability path amid quarterly volatility.

💰 Margins & Cash Flow

Operating margins remained robust, roughly 65% on average, underpinning strong profitability. Cash flow was solid from operating activities in multiple quarters, with occasional swings; 2026 Q2 posted a large negative net cash flow of about -$7.17B driven by financing/investing outflows, while earlier periods showed meaningful positive cash generation (e.g., late 2025 and early 2026).

🛡️ Balance Sheet & Liquidity

Balance sheet and liquidity are resilient: Total assets around $180–$200B; current assets ~$160–$166B vs current liabilities ~$149–$159B, yielding a near 1.0x to 1.1x current ratio. Equity near $26–$28B and noncurrent liabilities modest, indicating scope to absorb volatility.

⚠️ Key Drivers & Risks

• Drivers: Trading volume and rates/derivatives demand.
• Risks: Cyclicality of capital markets and regulatory/competitive pressure could compress volumes.